Biotech Startups

BioThermic Process Controls develops single-use technology for high-fidelity temperature control of precision fermentations, aimed at bioproduct manufacturers. Its systems are intended to improve first-pass quality and yield while lowering production costs across multiple industries.

1 investor

BioTissue develops regenerative medicine products derived from human birth tissue to treat wounds and chronic pain. The company's offerings have anti-inflammation and anti-scarring properties and are used by surgeons and healthcare professionals to help patients heal faster.

1 investor

Biotitan develops nanotechnology-based surface treatments with bactericidal and virucidal properties for various environments. The company offers tailored turnkey solutions, training, and custom application services.

1 investor

Biotix develops natural, sustainable skincare ingredients derived from skin microbiome microbes, using an AI platform alongside biology experiments to identify and test ingredients for efficacy and safety. Its lead ingredient, Probix, is a microbial fermentation-derived compound intended to reinforce natural skin functions and protect against environmental irritants.

1 investor

Biotree develops metabolomics and proteomics analysis platforms and services for research institutions and pharmaceutical companies, offering laboratory testing solutions, medical devices, and cloud-based lab information systems.

1 investor

BioVana structures clinical data and biospecimen collections across African health institutions to meet international standards for biomedical research and precision medicine. The company enables biotech, pharma, and academic organizations to access diverse, well-characterized cohorts from African research institutions.

1 investor

The company develops diagnostics and diagnostic solutions for laboratory technicians, physicians, and patients, prioritizing fast and reliable testing capabilities.

1 investor

BioVeritas uses fermentation technology to convert biomass into sustainable aviation fuels and bio-based chemicals, serving the aviation fuel, food ingredients, and specialty chemicals sectors.

1 investor

Biovox works with PLA (polylactic acid), a biobased polymer, and evaluates its use as a material for drug delivery devices such as autoinjectors. The company focuses on sustainable material solutions for medical/pharmaceutical device applications.

1 investor

BIOW develops solutions targeting the health effects of air pollution exposure, specifically investigating how bioavailable anions may support mitochondrial function and neural resilience in the context of neurodegenerative diseases and aging. The company conducts clinical research on biomarker changes and microbiome effects through advanced proteomics and metabolomics analysis.

1 investor

BioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

1 investor

Bioxis develops proprietary biomaterials based on chitosan and hyaluronic acid for aesthetic dermatology applications. The company creates tissue induction products designed to regenerate tissue and collagen with long-lasting effects.

1 investor

Bisc Therapeutics develops Bax inhibitor therapies designed to prevent retinal cell death and preserve vision in patients with retinal degenerative diseases such as age-related macular degeneration, glaucoma, and inherited retinal disorders. The company operates in the biotech/ophthalmology therapeutics space.

1 investor

B_Platform is a genomic analysis software that uses AI and big data to prioritize genetic variants and organize sequencing results for clinical interpretation. It supports multiple sequencing platforms and associates variants with patient phenotypes for healthcare professionals and clinical laboratories.

1 investor

Blackbird Laboratories is a nonprofit life sciences incubator that translates university research breakthroughs into venture-ready biotech companies focused on developing new medicines and enabling technologies.

1 investor

Blacksmith Medicines discovers and develops small molecule inhibitors of metal-dependent enzymes for oncology and infectious disease applications. The company uses chemistry-based drug discovery approaches to address unmet medical needs.

1 investor

Black Swan Biotech (BSB) is a biotechnology company developing antisense oligonucleotide (ASO) therapies for Motor Neuron Disease, with a focus on Amyotrophic Lateral Sclerosis (ALS). It uses genomic research to create gene-modulating treatments targeting the genetic drivers of MND.

1 investor

Blazar develops software and methods for biomedical and translational R&D teams to preserve the traceability, context, and interpretability of results, model outputs, and supporting evidence as data, models, instruments, and workflows change over time. It serves institutions working on biomarker programs, multi-site analysis, AI-enabled pathology, and translational research, and can be deployed on-premise, in private cloud, or within a controlled environment.

1 investor

1 investor

A biotech company focused on hemostasis and RNA therapeutics, with expertise across translational science, manufacturing, and commercialization.

1 investor

BOLD Longevity Growth (BLG) is a venture capital fund focused on investing in companies at the intersection of AI, longevity, and biotechnology. The fund aims to make longevity innovations accessible and affordable for broader populations.

1 investor

BliNK Biomedical develops treatments and therapeutics in the biopharmaceutical industry. The company is led by executives with extensive backgrounds in drug discovery, pharmaceutical development, and biotech commercialization.

1 investor

Bliss BioPharma is a biopharmaceutical company focused on the CMC development and commercialization of biologics, including therapeutic monoclonal antibodies, bispecific antibodies, ADCs, recombinant proteins, and vaccines.

1 investor

Everbloom develops next-generation noble fibers derived from protein waste as biodegradable, recyclable alternatives to synthetic and animal-based textiles like cashmere, wool, and silk. It targets luxury fashion supply chains, partnering with textile mills to provide sustainable materials with lower land, water, and greenhouse gas footprints.

1 investor